According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon.
According to the media release issued by the Sanpower Group, the company “plans to accelerate Provenge sales penetration in the United States and also align its own resources to introduce Provenge to China and other major markets in Asia.”
We’ll probably have to wait and see what that actually means, but in our humble opinion the ability to accelerate sales of Provenge here in the US will require some serious new data regarding the effectiveness and safety of Provenge rather earlier in the progression of higher-risk forms of prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: Provenge, sipuleucel-T |
THE "NEW" PROSTATE CANCER INFOLINK 
Not to mention that Prostvac must figure somehow into Provenge’s prospects!
I’m glad to see Valeant exit this scene! A few years ago Valeant decided the way to make money was to siphon bucks from the wallets of patients and insurers by drastically and abruptly raising prices on drugs developed by companies it acquired. Shameful!
Will they finally be able to stand on their own? That’s the $93,000.00 question.